Effects of body-resistance strengthening and tumor-suppressing granules on immune adhesion function of red blood cells and expression of metastasis protein CD44 in tumor cells of patients with esophageal carcinoma.
OBJECTIVE
To investigate the effects of Fuzheng Yiliu granules (body-resistance strengthening and tumor-suppressing granules) in patients with esophageal carcinoma.


METHODS
We compared the immune adherent properties of red blood cells (RBCs), the expression of metastasis protein CD44, and the metastasis inhibition factor nm23, in esophageal carcinoma tumor cells of patients before and after radiotherapy in the presence and absence of orally administered Fuzheng Yiliu granules. Sixty-three hospitalized patients with esophageal carcinoma were treated with standard radiotherapy and randomly divided into treatment group (n = 30) treated with both radiotherapy and Fuzheng Yiliu granules and control group (n = 33) given radiotherapy only. Blood samples and tumor tissue were obtained before and after 21 d of treatment. The rosette rates for complement receptor type 3b (C3bRR) and immune complex receptor (ICRR) on RBCs were measured by erythrocyte immunological methods. Expression of CD44 and nm23 in tumor tissue sections was determined by immunohistochemical staining with monoclonal antibodies CD44v6 ad nm23H-1, respectively.


RESULTS
The positivity of RBC-C3bRR before and after 21 d of treatment increased from 7.78% +/- 1.59% to 10.03% +/- 2.01% in the double treatment group, while it changed only slightly from 7.18% +/- 1.29% to 7.46% +/- 1.12% in the radiotherapy group. The positive rate for RBC-ICRR decreased from 37.68% +/- 2.51% to 22.55% +/- 1.65% after the double treatment, and from 37.28% +/- 2.41% to 24.69% +/- 1.91% in radiotherapy group at the same time points. The difference in erythrocyte immune adherent function between the two groups was significant (P < 0.01, t-test). The CD44(+)-cases were reduced from 21 (70.00%) to 12 (40.00%) after treatment with Fuzheng Yiliu granules, whereas the CD44(+)-cases (69.70%) in the radiotherapy group remained unchanged. The difference between the treatment (40.00%) and control (69.70%) groups was significant (P < 0.05). Although the nm23(+)-cases were increased from 4 (13.33%) to 6 (20.00%) in the double treatment group and from 6 (18.18%) to 7 (21.21%) in the radiotherapy group, the difference was not significant (P > 0.05).


CONCLUSIONS
Fuzheng Yiliu granules enhance the immune adhesion function of RBCs and reduce the number of CD44(+)-cells in esophageal carcinoma patients, suggesting a potential role of these Chinese herbals in suppression of invasion and metastasis of malignant cells. However, this anti-metastatic effect has yet to be validated in vivo.
Zhao
Jian-Xiong
JX
Institute of Combined Western and Chinese Traditional Medicine, Lanzhou University Medical School, 99 Donggangxi Road, Lanzhou 730000, Gansu Province, China. zhaojx-01@126.com
Li
Xue-Feng
XF
Wang
Xue-Xi
XX
D000368:Aged; D002277:Carcinoma / Q000276:immunology* / Q000473:pathology / Q000532:radiotherapy; D002448:Cell Adhesion / Q000187:drug effects; D003131:Combined Modality Therapy; D018450:Disease Progression; D004365:Drugs, Chinese Herbal / Q000494:pharmacology*; D004912:Erythrocytes / Q000187:drug effects* / Q000473:pathology; D004938:Esophageal Neoplasms / Q000276:immunology* / Q000473:pathology / Q000532:radiotherapy; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D018960:Hyaluronan Receptors / Q000378:metabolism*; D008297:Male; D008516:Medicine, Chinese Traditional / Q000379:methods*; D008875:Middle Aged; D009362:Neoplasm Metastasis
D004365:Drugs, Chinese Herbal; D018960:Hyaluronan Receptors; C514332:fuzheng yiliuyin
Blood. 1997 Sep 15;90(6):2217-33
9310473
Cancer Res. 1994 Apr 1;54(7):1812-7
8137296
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2003 Jun;23(6):421-2
12872392
Eur J Cardiothorac Surg. 2004 Aug;26(2):419-24
15296908
J Bioenerg Biomembr. 2000 Jun;32(3):247-58
11768308
Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):12160-4
1465456
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2001 Oct;21(10):760-2
12575611
Zhonghua Fu Chan Ke Za Zhi. 1989 Jul;24(4):215-6, 252
2533548
J Biol Chem. 1996 Oct 11;271(41):25107-16
8810265
Lancet. 1992 Oct 31;340(8827):1053-8
1357452
J Cancer Res Clin Oncol. 2004 Jun;130(6):334-8
14872339
Am J Pathol. 1989 Apr;134(4):733-9
2565087
Cell. 2003 Mar 7;112(5):659-72
12628186
Hum Pathol. 2003 Feb;34(2):136-42
12612881
J Natl Cancer Inst. 1988 Apr 6;80(3):200-4
3346912
Lancet. 1993 Oct 23;342(8878):1019-22
7692200
Cell. 1990 Jun 29;61(7):1303-13
1694723
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2003 Dec;23(12):908-10
14714361
Cancer Lett. 1999 Apr 26;138(1-2):139-44
10378785
Zhong Xi Yi Jie He Xue Bao. 2004 Jul;2(4):262-4
15339409